| Phase | Primary endpoint | Major eligibility criteria | Chemotherapy (intraperitoneal) | Chemotherapy (systemic) | Status |
Adjuvant | ||||||
NCT00992199 | II | Rate of peritoneal metastasis | T3-4NxM0 | Cisplatin and 5FU | Not specified | Unknown |
NCT00858338 | II | Toxicity | IB-IVM0 | Floxuridine | 5-FU and concurrent radiotherapy | Completed |
NCT00006038 | II | Efficacy and toxicity | T2N1-2M0 or T3-4NanyM0 | Floxuridine and leucovorin | Docetaxel, cisplatin and 5-FU | Completed |
NCT00002783 | II | Efficacy and toxicity | II-IVM0 | Floxuridine and leucovorin | Cisplatin and 5-FU | Completed |
NCT00004103 | II | RR and TTF | IB-IVM0 | Floxuridine and cisplatin | Cisplatin and irinotecan | Completed |
NCT01683864 | II/III | PC free survival | T2-4Nany and Pcyt+ | MMC and cisplatin (hyperthermic) | No | Recruiting |
NCT02205008 | III | RFS | Suspicious of serosal invasion | MMC and 5-FU | S-1 | Recruiting |
NCT01882933 | III | OS | T3/4, N+ or Pcyt+ | Oxaliplatin (hyperthermic) | No | Recruiting |
Palliative | ||||||
NCT02024841 | I | MTD and RD | Primary gastric cancer + PC or Pcyt+ | Docetaxel | Cisplatin and S-1 | Recruiting |
NCT01525771 | I/II | MTD in phase I; PFS at 6months in phase II | PC or Pcyt+ | Docetaxel | Cisplatin and capecitabine | Ongoing |
NCT01379482 | II | OS | Primary gastric cancer + PC | Cisplatin and doxorubicin (Hyperthermic) | FP-based | Completed |
NCT01854255 | II | CBR | PC | Cisplatin and doxorubicin (pressurized aerosal) | No | Recruiting |
NCT02092298 | II | OS | PC or Pcyt+ | MMC, cisplatin and sodium thiosulfate | No | Recruiting |
NCT01739894 | II | OS | PC or Pcyt+ | Paclitaxel | Oxaliplatin and capecitabine | Recruiting |
NCT01471132 | II | OS | PC or Pcyt+ | Oxaliplatin and paclitaxel (hyperthermic) | No | Recruiting |
NCT01342653 | II | DFS | PC | Docetaxel and cisplatin MMC and doxorubicin (hyperthermic) | 5-FU, docetaxel and cisplatin | Recruiting |
NCT01784900 | II | PFS | PC and CCR | Catumaxomab | No | Recruiting |
NCT01504256 | II | Rate of mCR of PC | PC | Catumaxomab | 5-FU, oxaliplatin and docetaxel | Recruiting |
NCT02158988 | III | OS | PC | MMC and cisplatin (hyperthermic) | Epirubicin, oxaliplatin and capecitabine +/− trastuzumab | Recruiting |